Market Overview

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Share:
Related TEVA
Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's Generic Nexium
Benzinga's Weekend M&A Chatter
Teva Gains FDA Nod for Generic of AstraZeneca's Nexium - Analyst Blog (Zacks)

On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49.

Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”

Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”

Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.

Latest Ratings for TEVA

DateFirmActionFromTo
Jan 2015JefferiesMaintainsBuy
Dec 2014Sterne AgeeUpgradesNeutralBuy
Dec 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Chris Schott JP MorganAnalyst Color Analyst Ratings

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters